Wellington Management Group LLP Has $28.32 Million Stock Holdings in Artivion, Inc. $AORT

Wellington Management Group LLP lifted its stake in Artivion, Inc. (NYSE:AORT) by 9.0% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,260,279 shares of the company’s stock after acquiring an additional 103,592 shares during the quarter. Wellington Management Group LLP owned approximately 2.58% of Artivion worth $28,318,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of AORT. Royal Bank of Canada increased its position in shares of Artivion by 107.0% during the 1st quarter. Royal Bank of Canada now owns 38,707 shares of the company’s stock worth $952,000 after purchasing an additional 20,010 shares during the last quarter. AQR Capital Management LLC grew its stake in shares of Artivion by 8.8% in the first quarter. AQR Capital Management LLC now owns 35,053 shares of the company’s stock valued at $862,000 after buying an additional 2,823 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Artivion by 4.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,591 shares of the company’s stock worth $580,000 after buying an additional 1,032 shares during the last quarter. Creative Planning increased its holdings in Artivion by 5.6% during the second quarter. Creative Planning now owns 14,272 shares of the company’s stock worth $444,000 after buying an additional 753 shares during the last quarter. Finally, Invesco Ltd. raised its position in Artivion by 40.8% during the second quarter. Invesco Ltd. now owns 481,026 shares of the company’s stock worth $14,960,000 after acquiring an additional 139,370 shares in the last quarter. Institutional investors own 86.37% of the company’s stock.

Insider Transactions at Artivion

In related news, CEO James P. Mackin sold 70,000 shares of the business’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $28.95, for a total value of $2,026,500.00. Following the completion of the sale, the chief executive officer directly owned 877,275 shares in the company, valued at $25,397,111.25. The trade was a 7.39% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, SVP Andrew M. Green sold 44,001 shares of the company’s stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $20.70, for a total value of $910,820.70. Following the completion of the transaction, the senior vice president directly owned 60,259 shares in the company, valued at approximately $1,247,361.30. This represents a 42.20% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 122,981 shares of company stock worth $3,181,531. Company insiders own 6.30% of the company’s stock.

Wall Street Analyst Weigh In

AORT has been the subject of a number of analyst reports. Needham & Company LLC reissued a “buy” rating and issued a $44.00 price objective on shares of Artivion in a research report on Monday, July 20th. Weiss Ratings cut shares of Artivion from a “sell (d+)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. Citigroup reiterated a “market outperform” rating on shares of Artivion in a research note on Tuesday, July 21st. Canaccord Genuity Group lifted their price target on Artivion from $39.00 to $40.00 and gave the stock a “buy” rating in a report on Tuesday, August 18th. Finally, Wall Street Zen lowered Artivion from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Seven equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $44.83.

Artivion Stock Performance

NYSE AORT opened at $25.59 on Friday. The stock has a market cap of $1.25 billion, a PE ratio of -365.52 and a beta of 1.25. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.51 and a current ratio of 3.47. The firm has a 50-day moving average of $26.09 and a 200-day moving average of $29.21. Artivion, Inc. has a 52-week low of $19.16 and a 52-week high of $48.25.

Artivion (NYSE:AORT) last announced its quarterly earnings results on Thursday, August 6th. The company reported $0.13 EPS for the quarter. The business had revenue of $125.76 million for the quarter, compared to analyst estimates of $119.99 million. Artivion had a negative net margin of 0.67% and a positive return on equity of 6.07%. On average, sell-side analysts anticipate that Artivion, Inc. will post 0.45 EPS for the current year.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.